Search the GHTC website

Global health R&D delivers for Arkansas

US government investment in global health R&D has delivered

$18.3 million
to Arkansas research institutions
200+ new jobs
for Arkansas
Arkansas's top USG-funded global health R&D institutions

Arkansas's top USG-funded global health R&D institutions

University of Arkansas
$15.9 million
Arkansas Children's Hospital
$831 thousand
$764 thousand
$693 thousand
BioDetection Instruments*
$176 thousand

Arkansas's top areas of global health R&D by USG funding

Neglected tropical diseases
Kinetoplastid diseases
Reproductive health
Diarrheal diseases
Multi-disease/health area R&D
Salmonella infections
Global health R&D at work in Arkansas

Scientists at the University of Arkansas for Medical Sciences (UAMS) have been awarded federal funding from the US National Institutes of Health (NIH) to support research on infectious diseases. This funding has enabled UAMS to establish the Center for Microbial Pathogenesis and Host Inflammatory Responses, which focuses on pathogens—bacteria, viruses, and microorganisms—and the disease responses they cause in humans. The center has advanced research on malaria, pneumonic plague, leishmaniasis—a parasitic disease that causes disfiguring skin lesions—and other deadly diseases. With NIH support, UAMS is also building a Pandemic Response and Public Health Laboratory equipped with Biosafety Level-3 labs to enable research on highly infectious diseases with pandemic potential. By trying to understand how pathogens cause disease in humans, the scientists hope to develop new treatments and technologies. One other new idea being developed at UAMS, in collaboration with the University of Arkansas at Little Rock, is a non-invasive malaria detection portable laser device for spotting parasite-infected cells traveling through blood vessels.

  • Methodology
  • US government global health R&D investment (total to state, top funded institutions, top health areas): Authors’ analysis of USG investment data from the G-FINDER survey following identification of state location of funding recipients. Reflects funding for basic research and product development for neglected diseases from 2007 to 2022, for emerging infectious diseases from 2014–2022, and sexual and reproductive health issues from 2018 to 2022. Funding to US government agencies reflects self-funding and/or transfers from other agencies. Some industry data is anonymized and aggregated. See methodology for additional details.
  • *Organization appears to be closed/out of business.
  • Jobs created: Based on author’s analysis described above and previous analysis assessing jobs created per state from US National Institutes of Health funding. See methodology for additional details.
  • Neglected and emerging diseases: Reflects US Centers for Disease Control and Prevention data for: Chikungunya virus cases 2014–2022, Dengue virus infection cases 2010-2021, HIV diagnoses 2008–2022, Malaria cases 2007–2022, Mpox cases 2022–March 29, 2023, Tuberculosis cases 2007–2021, Viral hemorrhagic fever cases 2007-2022, and Zika virus disease cases 2015–2021.
  • Case study photo: CDC/Melissa Dankel